Kositamongkol Chayanis, Kanchanasurakit Sukrit, Auttamalang Chiraphong, Inchai Nutkamon, Kabkaew Thanatchaporn, Kitpark Sarunporn, Chaiyakunapruk Nathorn, Duangjai Acharaporn, Saokaew Surasak, Phisalprapa Pochamana
Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Division of Pharmaceutical Care, Department of Pharmacy, Phrae Hospital, Phrae, Thailand.
Front Pharmacol. 2021 Dec 13;12:786596. doi: 10.3389/fphar.2021.786596. eCollection 2021.
The effects of coffee consumption on hepatic outcomes are controversial. This study investigated the associations between coffee consumption and the incidence of non-alcoholic fatty liver disease (NAFLD) in the general population and the reduction of liver fibrosis among patients with NAFLD. The study consisted of two parts: an umbrella review and a systematic review and meta-analysis (SRMA). The searches for each part were performed separately using PubMed, EMBASE, Cochrane, Scopus, and CINAHL databases. All articles published up to September 2021 were reviewed. To be eligible, studies for the umbrella review were required to report outcomes that compared the risks of NAFLD in the general population and/or liver fibrosis in patients with NAFLD who did and did not drink coffee. Our SRMA included primary studies reporting the effects of coffee consumption on NAFLD-related outcomes. The outcomes were pooled using a random-effects model and reported in both qualitative and quantitative terms (pooled risk ratio, odds ratio, and weighted mean difference). We identified four published SRMAs during the umbrella review. Most studies showed that individuals in the general population who regularly drank coffee were significantly associated with a lower NAFLD incidence than those who did not. Our SRMA included nine studies on the effects of coffee consumption on NAFLD incidence. Pooled data from 147,875 subjects showed that coffee consumption was not associated with a lower NAFLD incidence in the general population. The between-study heterogeneity was high ( , 72-85%). Interestingly, among patients with NAFLD (5 studies; = 3,752), coffee consumption was significantly associated with a reduction in liver fibrosis (odds ratio, 0.67; 95% CI, 0.55 to 0.80; , 3%). There were no differences in the coffee consumption of the general population and of those with NAFLD (4 studies; = 19,482) or by patients with no/mild liver fibrosis and those with significant fibrosis (4 studies; = 3,331). There are contrasting results on the effects of coffee on NAFLD prevention in the general population. Benefits of coffee consumption on liver fibrosis were seen among patients with NAFLD. : https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021226607, identifier CRD42021226607.
咖啡摄入对肝脏结局的影响存在争议。本研究调查了普通人群中咖啡摄入量与非酒精性脂肪性肝病（NAFLD）发病率之间的关联，以及NAFLD患者肝纤维化的减轻情况。该研究包括两个部分：一项系统综述和一项系统评价与荟萃分析（SRMA）。每个部分的检索分别使用PubMed、EMBASE、Cochrane、Scopus和CINAHL数据库进行。对截至2021年9月发表的所有文章进行了综述。纳入系统综述的研究需报告比较喝咖啡和不喝咖啡的普通人群中NAFLD风险以及NAFLD患者肝纤维化风险的结局。我们的SRMA纳入了报告咖啡摄入对NAFLD相关结局影响的原始研究。结局采用随机效应模型进行汇总，并以定性和定量方式报告（汇总风险比、比值比和加权平均差）。在系统综述过程中，我们确定了四项已发表的SRMA。大多数研究表明，普通人群中经常喝咖啡的个体与不喝咖啡的个体相比，NAFLD发病率显著较低。我们的SRMA纳入了九项关于咖啡摄入对NAFLD发病率影响的研究。来自147,875名受试者的汇总数据表明，普通人群中咖啡摄入与较低的NAFLD发病率无关。研究间异质性较高（I² = 72 - 85%）。有趣的是，在NAFLD患者中（5项研究；n = 3,752），咖啡摄入与肝纤维化减轻显著相关（比值比，0.67；95%置信区间，0.55至0.80；I² = 3%）。普通人群和NAFLD患者的咖啡摄入量（4项研究；n = 19,482）或无/轻度肝纤维化患者和显著纤维化患者的咖啡摄入量（4项研究；n = 3,331）没有差异。关于咖啡对普通人群NAFLD预防的影响存在相互矛盾的结果。在NAFLD患者中观察到了咖啡摄入对肝纤维化的益处。: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021226607，标识符CRD42021226607。
